Boston Scientific has announced the launch and first US implant of its line of extended longevity implantable cardioverter defibrillators, including the Dynagen and Inogen device models. The first extended longevity device was implanted at The University of Pittsburgh Medical Center by Samir Saba.
The devices feature EnduraLife battery technology that was developed with high-performance chemistry and advanced manufacturing capabilities to provide up to double the battery capacity of other implantable cardioverter defibrillators. Boston Scientific says that devices with similar technology have been shown to outperform competitors’ device longevities in several recent clinical studies, and the extended longevity line is projected to last nearly 12 years.
“Battery longevity has a direct impact on patient outcomes and the cost of care,” says Saba. “The extended longevity implantable cardioverter defibrillator is an important advancement that can help minimise the frequency of avoidable replacement procedures to help reduce costs and the potential for replacement-related complications.”
A company press release says that the EnduraLife battery technology delivers the industry’s longest projected longevity, and is packaged in a device up to 11% smaller and 24% thinner than devices from other manufacturers. Increased device longevity can reduce the risk of infection and other complications over time, minimise out-of-pocket patient expenses for avoidable replacement procedures, and decrease other healthcare system costs associated with device therapy.
“By providing a device with greater battery capacity, physicians are now able to offer patients a longer lasting device and increased peace of mind, while administrators and payors have new options to more effectively manage healthcare costs and minimise unexpected complications,” says Joe Fitzgerald, executive vice president and president, Rhythm Management, Boston Scientific.
